Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects, ages 18-65~* Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening~* Screening Knodell necroinflammatory score \>= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period~* ALT \> the upper limit of the normal range (ULN) but \< 10 X ULN at the screening visit~* Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy~* BMI between 19 and 36 kg/m2 (inclusive)~* Creatinine clearance \>= 70 mL/min~* absolute neutrophil count \>= 1000/mm3~* Hemoglobin \> 10 g/dL~* Have no clinical or laboratory evidence of hepatic decompensation~Exclusion Criteria:~* Decompensated liver disease~* Child-Pugh grade B or C cirrhosis~* Evidence of hepatocellular carcinoma~* Positive urine drug screen for cocaine or amphetamines~* Infection with HCV genotype 3~* Co-infection with hepatitis B virus or human immunodeficiency virus~* Pancreatitis~* Recent significant infection or symptoms of infection~* Autoimmune disorders~* Any history of seizure~* Is a public transportation operator (pilot of airplane or ship; air traffic controller; bus, train or subway driver) or operates heavy construction machinery~* Transplantation~* History of malignancy~* Current excessive alcohol ingestion, averaging \> 3 drinks/day for females and \> 4 drinks/day for males~* History of or current binge drinking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GS-9450 10 mg/day (Type: EXPERIMENTAL): GS-9450 taken as one 10 mg capsule by mouth once daily
- GS-9450 40 mg/day (Type: EXPERIMENTAL): GS-9450 taken as one 40 mg capsule by mouth once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo taken as one placebo capsule by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).